Aims: Accumulating evidence suggests that atherosclerotic progression depends on persistent and chronic inflammation in the arterial walls. MicroRNA-155 is reportedly involved in cardiovascular disease and has been implicated as a pro-inflammation regulator. Although some researchers have focused on microRNA-155 as an atherosclerosis regulator, the mechanisms by which microRNA-155 functions as a putative pro-atherosclerosis microRNA are largely unknown. This study aims to analyze microRNA-155's effects on atherosclerotic inflammation and to explore its mechanism. Methods: MicroRNA-155's effects on atherosclerotic inflammation were observed along with the expression and activity levels of SOCS1, STAT3 and NF-κB though microRNA-155 inhibition or overexpression. Results: Highly expressions of microRNA-155 in oxLDL-stimulated macrophages and atherosclerosis mice were inversely correlated with SOCS1 expression. Ectopic microRNA-155 overexpression significantly promoted inflammatory cytokine and chemokine production and atherosclerosis progression. We then observed microRNA-155's functional role in the atherosclerotic pathophysiological process in vivo and in vitro. The observation revealed that by enhancing STAT3 and NF-κB signaling and facilitating immune inflammation by targeting SOCS1, microRNA-155 plays a promotable role in atherosclerosis progression. Conclusions: microRNA-155 works as a promoter in the atherosclerotic procession. Its mechanism may include enhancing inflammatory response in atherosclerosis by increasing STAT3 and NF-κB signaling via targeting SOCS1.
Introduction
Atherosclerosis is one of the leading causes of morbidity and mortality worldwide. Its key cellular elements include hyperlipidemia, monocyte recruitment, differentiation into macrophages, foam cell formation, and induced inflammation [1] . Accumulating evidence
Quantitative RT-PCR
We performed quantitative RT-PCR analyses for miRNAs using TaqMan miRNA assays (Ambion) in a Rotorgene 6000 Thermocycler (Corbett Life Science), using the following parameters: 95°C for 20 s, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 70°C 10 s. We used U6 small nuclear RNA as an endogenous control for data normalization and calculated the relative expression using the comparative threshold cycle method.
hsa-miR-155 mimics: (5'to 3') F: UUAAUGCUAAUCGUGAUAGGGGU (5'to 3') R: ACCCCUAUCACGAUUAGCAUUAA hsa-miR-155 inhibitor: ACCCCUAUCACGAUUAGCAUUAA negative control for each one: mimics control: (5'to 3') F: UCACAACCUCCUAGAAAGAGUAGA (5'to 3') R: UCUACUCUUUCUAGGAGGUUGUGA Inhibitor control: (5'to 3') F: UCUACUCUUUCUAGGAGGUUGUGA We performed quantitative RT-PCR analyses for the mRNA using PrimeScript RT-PCR kits (Takara) and used the mRNA level of β-actin as an internal control. The real-time PCR program steps included: 95°C for 1 min, 40 cycles of 95°C for 5 s, 60°C for 5 s, and 72°C for 20 s. The primer sequences are shown as follows: SOCS1, 5′-CTT CTG TAG GAT GGT AGC ACA C -3′(sense), 5′-AGG AAG AGG AGG AAG GTT CT -3′ (anti-sense); TNF-α, 5′-GAT CCC TGA CAT CTG GAA TCT G -3′(sense), 5′-GAA ACA TCT GGA GAG AGG AAG G -3′ (antisense); IL-1β , 5′-CTC TCA CCT CTC CTA CTC ACT T-3′ (sense); 5′-TCA GAA TGT GGG AGC GAA TG -3′ (anti-sense); CCL2 , 5′-GCA GAA GTG GGT TCA GGA TT -3′ (sense); 5′-ATT CTT GGG TTG TGG AGT GAG -3′ (anti-sense); CCL4, 5′ -GTA CGT GTA TGA CCT GGA ACT G -3′ (sense), 5′-AGT CCT GAG TAT GGA GGA GAT G -3′ (anti-sense); CCL7, 5′-GGC TGA GAC CAA ACC AGA AA -3′ (sense), 5′-GTG AGC AGC AGA CAC AGA A -3′ (anti-sense); β-actin, 5′-GGA TCA GCA AGC AGG AGT ATG -3′ (sense), 5′-AGA AAG GGT GTA ACG CAA CTA A -3′ (anti-sense).
Western blot analysis
Protein extracts were denatured and the solubilized proteins (40μg) subjected to electrophoresis on 10% polyacryl amide SDS gels. We then probed with antibodies for SOCS1, STAT3, phospho-STAT3 (Abcam), I κBα, phosphor-I κBα, and β-actin (Santa Cruz) (diluted 1:500, β-actin diluted 1:2000 in TBST), and then we used goat anti-rabbit secondary antibody labeled with far-red-fluorescent Alexa Fluor 680 dye. We detected the immunofluorescence signal using a SuperSignal West Femto Maximum Sensitivity Substrate kit (ThermoPierce) and performed densitometric analysis using Image Lab (Bio-Rad).
ELISA assays
We analyzed cell or serum supernatants to determine the presence of TNF-α, IL-1β, CCL2, CCL4 and CCL7 using Enzyme Immunoassay kits (eBioscience or Uscn Life Science, Inc.) according to the manufacturer's instructions. The values were determined in more than three independent experiments and are represented as the means ±SD. We extracted nuclear proteins to assay NF-κB in each sample's nucleic protein using the Trans-AM NF-κB p50 Transcription Factor Assay Kit (Active Motif) according to the manufacturer's instructions.
In vivo assay
We purchased C57BL/6J mice from the Experimental Animal Center of the Third Military Medical University (Chongqing, China) and ApoE-/-mice from the BeiJing Xie He Medicine College (BeiJing, China). The 6-week-old male ApoE-/-mice (n=16) were fed a high-cholesterol diet (1.25% of cholesterol) for 12 weeks to build an atherosclerosis mouse model, and 6-week-old male C57BL/6 mice (n=8) were fed a normal diet as a control. ApoE gene knockout mice showed symptoms of high blood lipid abnormalities and were then divided into two groups (n=8): the first group was injected with mismatched miR-155 and the second with antagomiR-155(chemically modified antisense oligonucleotides). Mismatched miR-155 and antagomiR-155 were synthesized by GenePharma Co., Ltd. We began treatment 12 weeks after feeding mice a high-cholesterol diet, and they then received 0.2 ml saline and antagomir-155 via tail vein injections. They received three injections in three consecutive days at 80 mg/kg body weight [20, 21] . All animal studies were approved by the Animal Care and Ethics Committee of the Third Military Medical University. 
Cellular Physiology and Biochemistry
Analysis of atherosclerotic plaque size and composition Three weeks after antagomir-155 treatment, we anesthetized mice with an intraperitoneal chloral hydrate injection (5%, 4μl/g), took blood from the apical, and then separated and collected the thoracicabdominal aorta (spanning from the aortic arch to the iliac artery branch) after saline infusion. We performed morphometric and immunohistochemical studies in the thoracic-abdominal aorta and assessed lesion size and composition as previously described [22] .We took serial sections throughout the entire aortic valve area and routinely stained them with hematoxylin and eosin. To quantitate plaque size, we acquired the images of 3 sections with a DP70 digital camera connected to a microscope (Olympus) and determined lesion areas using Image-Pro plus v 6.0 software (Media Cybernetics, Inc.). We used the mean value of plaque cross-sectional areas from 3 sections to estimate the extent of atherosclerosis for each animal. We performed immunohistochemical analyses using the following primary antibodies: anti-mouse CD68 (Santa Cruz), anti-SOCS1 (Santa Cruz), and anti-SMA (Abcam). We analyzed at least 4 sections per animal for each immuno-staining.
Statistical analysis
We performed all statistical analyses using SPSS 19.0 software. Results are shown as the means ±SD. We determined statistical differences by Student's t-tests or one-way ANOVA. P-values< 0.05 were considered statistically significant.
Results

SOCS1 is a target of miR-155 in oxLDL-stimulated macrophages
To understand the biological role underlying the SOCS1-miR-155 interaction in atherosclerosis, we cloned the wild type and mutant SOCS1-3'UTR gene containing the miR-155 recognition site by inserting it downstream to a luciferase reporter. We then performed the dual luciferase assay in oxLDL-stimulated macrophages cotransfected with miR-155 mimic/inhibitor. Compared with the wild type SOCS1-UTR plasmid transfection, the relative luciferase activity was statistically significantly decreased or increased following cotransfection with miR-155 mimic or inhibitor (Fig. 1B, P<0 .01). Conversely, we observed no luciferase change in cells cotransfected with mutant SOCS1-UTR constructs (Fig. 1B, P>0 .05). For better detection, we transfected miR-155 mimic and inhibitor into oxLDL-induced macrophages. Results showed that miR-155 mimic led to a significant decrease, while miR-155 inhibitor led to an obvious increase of SOCS1 mRNA and protein levels, relative to the miR-155 control group transfected with a negative control miRNA (Fig.1C-D, P<0 .01).
Inverse correlation of miR-155 and SOCS1 in oxLDL-stimulated macrophages and in atherosclerosis model mice
To understand the biological role underlying the SOCS1-miR-155 interaction in atherosclerosis, we initially examined SOCS1 and miR-155 expression levels in oxLDLstimulated macrophages and in atherosclerosis model mice. Real-time PCR results showed significantly up-regulated miR-155 levels from oxLDL-stimulated macrophages from 24 to 72 h ( Fig. 2A , # P<0.01). Conversely, mRNA and protein levels of SOCS1 were gradually decreased from 24 to 72 h after oxLDL stimulation (Fig. 2B-C , # P<0.01). Furthermore, we examined SOCS1 and miR-155 expressions in 16 thoracic-abdominal aorta samples (vessel tissue) from atherosclerosis mice and paired C57BL/6 mice. As expected, miR-155 levels were commonly and significantly elevated in atherosclerosis mice samples, and SOCS1 mRNA was obviously reduced in atherosclerosis mice compared to C57BL/6 mice (Fig. 2D) . Using Pearson's correlation analysis of SOCS1-miR-155 expression, we obtained a statistically significant inverse correlation (R=−0.892,P= 0.000) (Fig. 2D) .
These collective results indicate that miR-155 expression is inversely correlated with SOCS1 expression in oxLDL-stimulated macrophages and in atherosclerosis mice, suggesting that SOCS1-miR-155 interactions may have biological significance in atherosclerosis. 
miR-155 promoted inflammation and macrophage migration in oxLDL-stimulated macrophages
To further study miR-155's role in the atherosclerosis inflammatory response, we used miR-155 inhibitor and mimic in oxLDL stimulated macrophages. Results showed that secretions of inflammatory cytokines TNF-α and IL-1β, as well as chemokines CCL2, CCL4 and CCL7, were decreased after miR-155 inhibitor treatment, and this decrease could be counteracted by miR-155 mimic (Fig.3A-B , *P<0.01). For better detection, we used siRNAs to knockdown SOCS1 in oxLDL-stimulated macrophages. The SOCS1 expression knockdown via siRNA treatment efficiently repressed SOCS1 mRNA and protein levels (Fig.  3C-D , *P<0.01). As expected, SOCS1 knockdown led to increased TNF-α, IL-1β, CCL2, CCL4 and CCL7, at both the mRNA and protein levels. These observations were similar to those results following miR-155 mimic treatment (Fig.3E-F, *P<0.01) . The results of transwell showed that miR-155 overexpression or SOCS1 knockdown with its specific siRNA led to increased macrophage migration, whereas when miR-155 was downregulated by inhibitor, the migrated macrophages decreased statistically (Fig.3G, *P<0 .01).
miR-155 enhanced STAT3 and NF-κB signaling in oxLDL-stimulated macrophages
SOCS1 is a tumor suppressor that normally functions as a negative feedback regulator of JAK/STAT signaling [18] . Recent evidence indicates that STAT3 collaborates with NF-κB to regulate certain gene expressions [23] . Therefore, we were interested in determining the involvement of STAT3 and NF-κB signaling in miR-155's inflammatory effect. We transfected oxLDL-stimulated macrophages with miR-155 inhibitor, miR-155 mimic, and siSOCS1. Western blot results showed that miR-155 inhibitor significantly downregulated STAT3 and IκBα phosphorylation, but siSOCS1 and miR-155 mimic increased the phosphorylation (Fig.  4A-B) . Furthermore, miR-155 inhibitor could downregulate, iSOCS1 and miR-155 mimic could upregulate NF-κB activity in oxLDL in macrophages (Fig. 4C) .
Inhibition of miR-155 attenuated atherosclerosis development and inflammation in an atherosclerosis mouse model
To test whether miR-155 inhibition was beneficial for atherosclerosis, we blocked miR-155 via tail-vein antagomir-155 injection in ApoE -/-mice with a high-fat diet. Real-time PCR analysis showed that antagomir-155 significantly inhibited miR-155 levels in the mice's plasma, vessel tissues (thoracic-abdominal aortas) and BMMCs (Fig.5A, P<0.05) . Meanwhile, we detected an obvious SOCS1 increase in both mRNA and protein levels in the antagomir-155 group (Fig.5B, P<0 .05). We separated the mice's thoracic-abdominal aortas to observe the atherosclerotic lesions and analyzed the results using IPP 6.0 software. Consistent with the above results, the SOCS1-positive area was increased after antagomir-155 treatment (Fig.5C,  P<0 .05). Although the lesion areas did not decrease after antagomiR-155 treatment, we observed a decrease in the positive area for atherosclerosis plaque macrophages (CD68), an increase in collagen deposition and the SMA-positive area in the antagomiR-155-treated group compared to the antagomir negative control (Fig. 5C, P<0.01) .
Additionally, TNF-α, IL-1β, CCL2, CCL4, and CCL7 secretions in serum, vascular tissues and BMMCs were significantly downregulated by antagomir-155 compared to the antagomir negative control (Fig. 6D-E, P<0 .01). STAT3 and NF-κB signaling were inhibited after antagomir-155 treatment (Fig. 6F-G, P<0.01 ). These data show that inhibiting miR-155 reduces macrophage accumulation and alleviates inflammation in atherosclerosis, suppresses atherosclerotic plaque development.
Discussion
Accumulating evidence suggests that inflammation drives the formation, progression, and rupture of atherosclerotic plaques [23] . Therefore, focusing on the potential targets of inflammatory processes in atherosclerosis would provide novel treatment strategies [2] .
Many miRNAs play an important role in atherogenesis [10, [24] [25] [26] . For example, miR-126 is reportedly an anti-atherosclerosis microRNA since it regulates angiogenesis and vascular inflammation [27] and miR-150 promotes atherosclerosis via enhancing the targeted endothelial cell migration [28] . miR-155 may be one miRNA which plays an important role in atherosclerosis. It reportedly increases in ACS patients and could promote atherosclerosis by repressing Bcl6 in macrophages [14] . Wei Y et al. reported that the microRNA-342-5p could foster inflammatory macrophage activation through an Akt1-and microRNA-155-dependent pathway during atherosclerosis [17] . Qing Jing et al. found that elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis [29] . Among miR-155's targets, SOCS1 attracted our attention. SOCS1 is a powerful attenuator of JAK/STAT signaling [30] and has more recently been shown to disrupt NF-κB and the JNK and p38 pathways [23, 31] . Activation of NF-κB is reported to be higher in patients with ACS and in oxLDL-induced mast cells [32, 33] . Also, STAT3 signal pathway is reported to be involved in atherosclerosis inflammation [34] . Thus, we wished to investigate the role of SOCS1-miR-155 in regulating the atherosclerotic vascular inflammation response to find new therapeutic strategies for treating atherosclerosis and other vascular diseases.
First, we confirmed SOCS1 as a target of miR-155 in oxLDL-induced macrophages. We then observed miR-155 and SOCS1 levels in oxLDL-stimulated macrophages and in atherosclerosis model mice. We noticed a statistically significant inverse correlation between Considering miR-155 is involved in some aspects of the atherosclerotic pathological process and inflammation [29, 35, 36] , we hypothesized that SOCS1-miR-155 was deeply involved in regulating atherosclerosis inflammation. The present results showed that ectopic high levels of miR-155 as well as siSOCS1 could increase, and blocking miR-155 could decrease the production and secretion of some pro-inflammatory cytokines and chemokine in oxLDL-stimulated macrophages, which could lead to increased monocyte recruitment to plaque and promote atherosclerosis progression. These results confirmed our hypothesis that miR-155 acts as a promoter of inflammation in oxLDL-stimulated macrophages partly via targeting SOCS1. miR-155 greatly influenced the production and secretion of inflammatory cytokines and chemokines, SOCS1 functions most classically to limit IFN activation of STATs(namely STAT1, STAT2, and STAT3) [37, 38] . Ryo A et al. gave evidence indicating that STAT3 collaborates with NF-κB to regulate certain gene expressions [23] , and Guo J et al. reported IKBKE as a direct target of STAT3 [39] , which could activate NF-κB and STAT signaling [39, 40] . Our results also showed that miR-155 could enhance STAT3 and NF-κB signaling in oxLDL-stimulated macrophages. Furthermore, we noticed that siSOCS1 was less efficient than miR-155 mimic at inducing atherosclerosis inflammation, suggesting that other targets might be involved in miR-155's promotable function in oxLDL-stimulated macrophages. Upon using antagomir-155 to block miR-155 expression in ApoE -/-mice with high fat diets, the positive area for atherosclerosis plaque macrophages decreased, the collagen deposition and the SMA-positive area increased, suggesting that the plague may be stable, although the lesion area was increased slightly, the continuous high-fat diet could be one of the important reasons. Besides, we noticed that inhibiting miR-155 alleviated inflammation, as well as STAT3 and NF-κB signaling in vivo.
The present study's collective results suggested miR-155's pro-atherosclerotic effect occurs by promoting atherosclerosis inflammation partially via targeting SOCS1 to enhance STAT3 and NF-κB signaling. Considering antagomir-155 has clinically acceptable virtues like easy dose control, drug-like properties, and high effectiveness in over-expressing target miRNA with long-lasting efficacy under in vivo conditions [41, 42] , it may offer some new insights regarding atherosclerosis treatment [43] .
